Zai Lab Announces NMPA Approval of ZEJULA® (Niraparib) in China as Maintenance Therapy for Patients with Recurrent Ovarian Cancer
Zai Lab Limited - American Depositary Shares (ZLAB)
US:NASDAQ Investor Relations:
zailaboratory.com/about/investors.php
Company Research
Source: GlobeNewswire
ZEJULA is a potential best-in-class PARP inhibitor for ovarian cancer patients due to its compelling clinical data1, once-daily dosing and pharmacokinetic properties ZEJULA is the first approval for Zai Lab in Mainland China SHANGHAI, China and SAN FRANCISCO, Dec. 27, 2019 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB), a China and U.S.-based innovative commercial stage biopharmaceutical company, today announced the China National Medical Products Administration (NMPA) approved the New Drug Application (NDA) for ZEJULA (niraparib), an oral, once-daily poly (ADP-ribose) polymerase (PARP) inhibitor as maintenance therapy for adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy. ZEJULA is a potent and highly selective PARP1/2 inhibitor that does not require BRCA mutation or other biomarker testing prior to administration. “The NMPA approval of ZEJULA, our first pro
Show less
Read more
Impact Snapshot
Event Time:
ZLAB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ZLAB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ZLAB alerts
High impacting Zai Lab Limited - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
ZLAB
News
- Zai Lab Announces Participation in Investor Conference in January 2025 [Yahoo! Finance]Yahoo! Finance
- Zai Lab Announces Participation in Investor Conference in January 2025Business Wire
- Novocure Has Already Doubled in 2024. Can It Soar Higher in 2025? [Yahoo! Finance]Yahoo! Finance
- Novocure seeks approval after pancreatic cancer wearable scores at Phase III [Yahoo! Finance]Yahoo! Finance
- NovoCure's Tumor-Treating Electric Fields Shows Promise In Pancreatic Cancer Patients [Yahoo! Finance]Yahoo! Finance
ZLAB
Earnings
- 11/12/24 - Beat
ZLAB
Sec Filings
- 12/13/24 - Form 4
- 11/15/24 - Form 8-K
- 11/15/24 - Form 424B5
- ZLAB's page on the SEC website